1 / 6

The pharmaceutical R&D process

10-12 years, costly ($30 Mn – $1300Mn). The pharmaceutical R&D process. Development. Discovery. Use. Discovery research = innovative part. development. Compound libraries. Drug candidate. Risks in research and development of pharmaceutical drugs. Reasons for failure include:

ebilly
Télécharger la présentation

The pharmaceutical R&D process

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 10-12 years, costly ($30 Mn – $1300Mn) The pharmaceutical R&D process Development Discovery Use

  2. Discovery research = innovative part development Compound libraries Drug candidate

  3. Risks in research and development of pharmaceutical drugs • Reasons for failure include: • Lack of bioavailability • Toxicity • Lack of efficacy • But also: • Patent position • Market prospect / competitors • Mergers/acquisitions development

  4. Therapeutic innovation :many different ways to innovate including new or better uses of existing molecules / treatments • Existing compounds: Library screening & compound mining • New compounds through medicinal chemistry • New uses of existing compounds • New indications of existing drugs • Improved formulationsof existing drugs • Completing registration dossier • Geographical extension • Combination treatments • Simplifying use • Changing guidelines • EML

  5. Compound mining:creative utilization of existing knowledge Nitroimidazoles: rediscovered drug candidates for protozoal diseases Extensive literature / patent review, including personal consultations with researchers (previously) active on this class of compounds to uncover possible compounds of interest >600 compounds identified from >15 sources; assessed in in vitro / in vivo disease models; several series with promising activity identified 1 new drug candidate in clinical development for sleeping sickness: fexinidazole (off-patent):

More Related